LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the completion of its Biologics License Application (BLA) submission ...

Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease that affects somewhere between 4 and 40 people per million worldwide. The condition causes substances such as fats and proteins ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced its financial results for the fourth quarter and fiscal year 2024, ...

Playing tag, riding bikes, and climbing trees are among the many joys of childhood that leave kids happily worn out and panting heavily for air. For those with lung disorders, growing up can look ...

(RTTNews) - Savara Inc. (SVRA), a biopharmaceutical company, Thursday announced that it has introduced the aPAP ClearPath Dried Blood Spot Test in the U.S. This new test builds on its prior serum ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with ...

-- The Simple, No-cost Test Can Detect Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Autoantibodies in the Blood with Only a Finger Prick -- Savara Inc. (Nasdaq: SVRA) (the Company), a ...